Company
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUL 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action establishing a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; it reflects a regulatory requirement, not a clinical trial outcome.
MAY 8, 2026 · REGULATORY APPROVAL
U.S. Food and Drug Administration
FDA approval of a generic intravenous levetiracetam formulation; regulatory action, not a clinical trial or efficacy study.
APR 15, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for zoledronic acid labeling change; does not report clinical trial outcomes or comparative efficacy.